Concord Biotech Ltd NSE:CONCORDBIO:
CONCORD BIOTECH LTD - TO EXPAND OPERATIONS IN USA
Concord Biotech To Expand Operations In USA
Earlier from Concord Biotech
- CONCORDBIO: 18% revenue growth, strong margins, new injectables, and global expansion drive performance
- Anthropic expert accused of using AI-fabricated source in copyright case
- CONCORDBIO: Stable Q3 with strong margins and 10% nine-month revenue growth; 25% CAGR outlook maintained
- Jigar Patel sees Nifty climbing towards 25,000, bets on these 3 stocks ideas for short term
- CONCORDBIO: Q2FY25 revenue rose 18% year-over-year, driven by a 125% increase in formulation sales
Later from Concord Biotech
- Concord Biotech Announces Successful Completion of EU GMP Inspection
- CONCORDBIO: Revenue down 5% YoY; injectables, CDMO, and US/India expansion drive future growth
- Taking Stock: Market rally continues for 6th day; Nifty fails to hold 25,100
- 10 stocks that will start trading ex-dividend from this week
- Concord Biotech dividend ex-date due tomorrow for Rs 10.7 per share payout; last day to trade today
Follow Concord Biotech into a list and get an email when it puts out news.
Follow Concord Biotech